Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352413 | 1.00 | PDGFRB (0.42) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL1750140 | 0.88 | GAA (0.49) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL4253950 | 0.88 | GAA (0.49) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL4299094 | 0.88 | GAA (0.49) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL29276828 | 0.88 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL29276789 | 0.88 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL29276792 | 0.88 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL24681112 | 0.82 | FPR1 (0.43) | MCHR1HTR2BHTR6KCNH2SOS1 | |
| SCHEMBL3538834 | 0.82 | NTSR1 (0.47) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL4263614 | 0.81 | FPR1 (0.44) | PDGFRBFGFR1KDRMAP4K4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | PDGFRB 700/4885FGFR1 1607/4885KDR 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.